Inter Partes Review: Patent Killer No More?

doi:10.1016/j.tibtech.2019.02.006

標題:	Inter Partes Review: Patent Killer No More?
作者:	Chen, Feng-Chi Lee, Pin-Shen 科技法律學院 College of Law
公開日期:	1-Jul-2019
摘要:	Inter Partes review (IPR) can efficiently invalidate drug patents and potentially convey strategic advantages to follow-on drug makers. However, recent changes in the IPR system foretell a tectonic shift in the landscape. Here we summarize these major changes and discuss the implications for the biopharmaceutical community.
URI:	http://dx.doi.org/10.1016/j.tibtech.2019.02.006 http://hdl.handle.net/11536/152312
ISSN:	0167-7799
DOI:	10.1016/j.tibtech.2019.02.006
期刊:	TRENDS IN BIOTECHNOLOGY
Volume:	37
Issue:	7
起始頁:	680
結束頁:	683
Appears in Collections:	Articles